clinical trial · NCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
UnresectableLocally AdvancedMetastatic CancersRelapsed/Refractory LymphomasREC-1245
brief summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
started
Nov 21, 2024
primary completion
Oct 30, 2028
completion
Oct 30, 2028
last updated
May 8, 2026
detailed description
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of REC-1245 for the treatment of participants with unresectable locally advanced or metastatic solid tumors. Participants will receive treatment with REC-1245 for up to 2 years.
official title
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol